PCSK9药物性与遗传性下调与脓毒症生存
该研究整合9个脓毒症人类队列(总n=12,514)的遗传学分析、ODYSSEY OUTCOMES(n=18,884)的事后分析及小鼠脓毒症模型,探讨PCSK9抑制对脓毒症结局的影响。人类队列中,遗传性PCSK9功能缺失变异与脓毒症28天死亡的OR=0.86(95%CI 0.67-1.10;p=0.24),在抗生素治疗患者中关联显著。ODYSSEY OUTCOMES中脓毒症发生率和死亡率均较低,阿利西尤单抗组与安慰剂组无显著差异,但阿利西尤单抗组脓毒症死亡相对风险为0.62(95%CI 0.32-1.20;p=0.15)。小鼠接受阿利西尤单抗5 mg/kg或25 mg/kg皮下注射后内毒素水平降低、生存改善。作者结论认为PCSK9抑制可能在预防性、预处理场景中改善脓毒症临床结局。
要点
- 9个脓毒症人类队列(总n=12,514)中,遗传性PCSK9功能缺失与脓毒症28天死亡的OR=0.86(95%CI 0.67-1.10;p=0.24),未达统计学显著。
- 上述遗传关联在抗生素治疗患者中显著。
- ODYSSEY OUTCOMES事后分析(n=18,884)中,阿利西尤单抗组 vs 安慰剂组脓毒症死亡相对风险0.62(95%CI 0.32-1.20;p=0.15),未达统计学显著。
- 小鼠在诱导细菌性脓毒症前48小时皮下注射阿利西尤单抗5 mg/kg或25 mg/kg,内毒素水平降低、生存改善,小鼠未接受其他脓毒症治疗。
- 作者结论:PCSK9抑制可能在预防性、预处理场景中改善脓毒症临床结局。
适用人群与场景
- 9个人类脓毒症队列,总n=12,514,用于评估遗传性PCSK9功能缺失变异与脓毒症死亡率的关联。
- ODYSSEY OUTCOMES(NCT01663402)为纳入心血管疾病患者的3期随机临床试验,事后分析评估18,884例参与者的脓毒症发生率或致死性脓毒症。
- 小鼠实验使用C57Bl/6J小鼠,建立铜绿假单胞菌和金黄色葡萄球菌菌血症脓毒症模型及脂多糖诱导的动物模型。
处置流程与药物剂量
- 小鼠在诱导细菌性脓毒症前48小时皮下注射PCSK9抑制剂阿利西尤单抗5 mg/kg或25 mg/kg,或同型匹配对照;小鼠未接受其他脓毒症治疗。
- ODYSSEY OUTCOMES参与者随机接受阿利西尤单抗或安慰剂。
研究设计与关键结果
- 研究设计:遗传与临床流行病学分析及实验模型,包括9个人类脓毒症队列(总n=12,514)、ODYSSEY OUTCOMES事后分析(n=18,884)及小鼠脓毒症模型。
- 人类队列中,遗传性PCSK9功能缺失与脓毒症诊断后28天死亡的效应估计为OR=0.86(95%CI 0.67-1.10;p=0.24)。
- 在抗生素治疗患者中,遗传性PCSK9功能缺失与脓毒症死亡存在显著关联。
- ODYSSEY OUTCOMES中脓毒症频率和死亡率均较低,组间无显著差异;阿利西尤单抗组 vs 安慰剂组脓毒症死亡相对风险0.62(95%CI 0.32-1.20;p=0.15),数值上较低。
- 小鼠接受阿利西尤单抗后内毒素水平降低、生存改善。
证据类型、等级与局限
- 证据类型:人类遗传学队列研究、3期随机临床试验事后分析及实验小鼠模型。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,PCSK9抑制可能在预防性、预处理场景中改善脓毒症临床结局;该结论基于遗传关联、临床试验事后分析及小鼠模型,未给出急诊或ICU床旁用药推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Treatments that prevent sepsis complications are needed. Circulating lipid and protein assemblies-lipoproteins play critical roles in clearing pathogens from the bloodstream. We investigated whether early inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) may accelerate bloodstream clearance of immunogenic bacterial lipids and improve sepsis outcomes.
DESIGN: Genetic and clinical epidemiology, and experimental models.
SETTING: Human genetics cohorts, secondary analysis of a phase 3 randomized clinical trial enrolling patients with cardiovascular disease (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab [ODYSSEY OUTCOMES]; NCT01663402), and experimental murine models of sepsis.
PATIENTS OR SUBJECTS: Nine human cohorts with sepsis (total n = 12,514) were assessed for an association between sepsis mortality and PCSK9 loss-of-function (LOF) variants. Incident or fatal sepsis rates were evaluated among 18,884 participants in a post hoc analysis of ODYSSEY OUTCOMES. C57BI/6J mice were used in Pseudomonas aeruginosa and Staphylococcus aureus bacteremia sepsis models, and in lipopolysaccharide-induced animal models.
INTERVENTIONS: Observational human cohort studies used genetic PCSK9 LOF variants as instrumental variables. ODYSSEY OUTCOMES participants were randomized to alirocumab or placebo. Mice were administered alirocumab, a PCSK9 inhibitor, at 5 mg/kg or 25 mg/kg subcutaneously, or isotype-matched control, 48 hours prior to the induction of bacterial sepsis. Mice did not receive other treatments for sepsis.
MEASUREMENTS AND MAIN RESULTS: Across human cohort studies, the effect estimate for 28-day mortality after sepsis diagnosis associated with genetic PCSK9 LOF was odds ratio = 0.86 (95% CI, 0.67-1.10; p = 0.24). A significant association was present in antibiotic-treated patients. In ODYSSEY OUTCOMES, sepsis frequency and mortality were infrequent and did not significantly differ by group, although both were numerically lower with alirocumab vs. placebo (relative risk of death from sepsis for alirocumab vs. placebo, 0.62; 95% CI, 0.32-1.20; p = 0.15). Mice treated with alirocumab had lower endotoxin levels and improved survival.
CONCLUSIONS: PCSK9 inhibition may improve clinical outcomes in sepsis in preventive, pretreatment settings.
参考来源
- Lawler PR, Manvelian G, Coppi A, et al. Pharmacologic and Genetic Downregulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Survival From Sepsis. Crit Care Explor. 2023. PMID: 37954898. doi:10.1097/CCE.0000000000000997
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。